Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klebsiella pneumoniae | 5 | 2020 | 73 | 0.950 |
Why?
|
| beta-Lactamases | 5 | 2020 | 192 | 0.730 |
Why?
|
| Tuberculosis, Pulmonary | 8 | 2009 | 216 | 0.670 |
Why?
|
| Bacterial Proteins | 6 | 2020 | 887 | 0.650 |
Why?
|
| Guinea Pigs | 13 | 2009 | 167 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 12 | 2024 | 2425 | 0.560 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2024 | 790 | 0.550 |
Why?
|
| Candidemia | 4 | 2023 | 40 | 0.500 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 681 | 0.490 |
Why?
|
| BCG Vaccine | 6 | 2007 | 109 | 0.460 |
Why?
|
| Klebsiella Infections | 4 | 2017 | 52 | 0.460 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 102 | 0.430 |
Why?
|
| beta-Lactam Resistance | 1 | 2013 | 46 | 0.430 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2018 | 364 | 0.420 |
Why?
|
| Cephalosporins | 3 | 2024 | 137 | 0.380 |
Why?
|
| Antimicrobial Stewardship | 2 | 2023 | 84 | 0.350 |
Why?
|
| Cross Infection | 4 | 2014 | 329 | 0.340 |
Why?
|
| Candida | 4 | 2023 | 75 | 0.340 |
Why?
|
| Minocycline | 2 | 2022 | 36 | 0.330 |
Why?
|
| Mycobacterium bovis | 2 | 2007 | 30 | 0.310 |
Why?
|
| Antigens, CD | 2 | 2007 | 422 | 0.300 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2007 | 378 | 0.280 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 265 | 0.280 |
Why?
|
| Leukocytes | 3 | 2007 | 206 | 0.270 |
Why?
|
| Drug Utilization | 3 | 2020 | 162 | 0.270 |
Why?
|
| Hospitals, University | 4 | 2014 | 97 | 0.270 |
Why?
|
| Antifungal Agents | 5 | 2023 | 290 | 0.250 |
Why?
|
| Carbapenems | 2 | 2015 | 35 | 0.220 |
Why?
|
| Vaccination | 3 | 2009 | 952 | 0.220 |
Why?
|
| Eosinophils | 1 | 2004 | 121 | 0.210 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 93 | 0.200 |
Why?
|
| Tuberculosis Vaccines | 3 | 2009 | 13 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1017 | 0.200 |
Why?
|
| Lung | 4 | 2009 | 1491 | 0.190 |
Why?
|
| Communicable Diseases | 1 | 2023 | 160 | 0.190 |
Why?
|
| Macrophages, Peritoneal | 3 | 2006 | 38 | 0.180 |
Why?
|
| Doxycycline | 2 | 2022 | 117 | 0.180 |
Why?
|
| Feces | 2 | 2015 | 718 | 0.170 |
Why?
|
| Ceftazidime | 1 | 2020 | 41 | 0.170 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 132 | 0.170 |
Why?
|
| Clostridium Infections | 2 | 2014 | 245 | 0.170 |
Why?
|
| Urine | 1 | 2020 | 90 | 0.170 |
Why?
|
| Ceftriaxone | 1 | 2018 | 68 | 0.150 |
Why?
|
| Peritonitis | 1 | 2018 | 75 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 171 | 0.140 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 1 | 0.140 |
Why?
|
| Bacteremia | 3 | 2017 | 407 | 0.140 |
Why?
|
| Texas | 8 | 2021 | 3590 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2015 | 117 | 0.140 |
Why?
|
| Immunization, Secondary | 2 | 2009 | 103 | 0.140 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 55 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 500 | 0.130 |
Why?
|
| Bacteria | 2 | 2018 | 484 | 0.130 |
Why?
|
| Spleen | 3 | 2007 | 282 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1708 | 0.130 |
Why?
|
| Echinocandins | 4 | 2023 | 44 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 166 | 0.130 |
Why?
|
| Health Personnel | 1 | 2021 | 505 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 510 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2018 | 305 | 0.120 |
Why?
|
| Humans | 31 | 2024 | 124793 | 0.120 |
Why?
|
| Fluconazole | 2 | 2012 | 47 | 0.120 |
Why?
|
| Meningitis | 1 | 2015 | 98 | 0.120 |
Why?
|
| Gram-Positive Bacteria | 1 | 2014 | 46 | 0.110 |
Why?
|
| Candida glabrata | 1 | 2014 | 18 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1309 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 76 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2015 | 175 | 0.110 |
Why?
|
| Candidiasis, Invasive | 1 | 2014 | 19 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2013 | 48 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2014 | 134 | 0.110 |
Why?
|
| Lipopeptides | 3 | 2023 | 33 | 0.100 |
Why?
|
| Rifamycins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Peptidomimetics | 1 | 2013 | 11 | 0.100 |
Why?
|
| Candidiasis | 1 | 2014 | 129 | 0.100 |
Why?
|
| Biological Therapy | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 68 | 0.100 |
Why?
|
| Macrophage Activation | 3 | 2006 | 62 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1019 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2013 | 463 | 0.090 |
Why?
|
| Intensive Care Units | 3 | 2023 | 485 | 0.090 |
Why?
|
| Animals | 13 | 2009 | 34184 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 135 | 0.080 |
Why?
|
| Cross Reactions | 2 | 2007 | 193 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 1393 | 0.080 |
Why?
|
| Aged | 10 | 2018 | 19691 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 2704 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 117 | 0.080 |
Why?
|
| Middle Aged | 11 | 2018 | 26716 | 0.080 |
Why?
|
| Tuberculosis, Pleural | 2 | 2005 | 8 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2044 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2006 | 264 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2007 | 151 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 672 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2015 | 6137 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 236 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6521 | 0.070 |
Why?
|
| Physicians | 1 | 2012 | 582 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 692 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 48 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2005 | 34 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 803 | 0.060 |
Why?
|
| Granuloma | 1 | 2005 | 68 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2005 | 114 | 0.060 |
Why?
|
| Phenotype | 1 | 2013 | 4260 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2003 | 136 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 503 | 0.050 |
Why?
|
| Female | 12 | 2018 | 66553 | 0.050 |
Why?
|
| Male | 11 | 2018 | 61283 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 134 | 0.050 |
Why?
|
| Cytokines | 2 | 2005 | 1290 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 1110 | 0.050 |
Why?
|
| Vancomycin | 2 | 2014 | 219 | 0.050 |
Why?
|
| Adult | 6 | 2023 | 29471 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 298 | 0.050 |
Why?
|
| Tuberculosis | 2 | 2005 | 519 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2022 | 143 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 2451 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 459 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.050 |
Why?
|
| Azabicyclo Compounds | 1 | 2020 | 16 | 0.040 |
Why?
|
| Masks | 1 | 2021 | 38 | 0.040 |
Why?
|
| Mutation | 1 | 2014 | 5811 | 0.040 |
Why?
|
| Base Sequence | 1 | 2005 | 3099 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 54 | 0.040 |
Why?
|
| Rabbits | 3 | 2006 | 711 | 0.040 |
Why?
|
| Hospitals, Religious | 1 | 2020 | 6 | 0.040 |
Why?
|
| Catholicism | 1 | 2020 | 6 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1587 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10272 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 276 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3287 | 0.040 |
Why?
|
| Phylogeny | 2 | 2017 | 696 | 0.040 |
Why?
|
| Salmonella enterica | 1 | 1998 | 9 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1998 | 107 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 12342 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 3881 | 0.040 |
Why?
|
| DNA, Bacterial | 2 | 2015 | 474 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 115 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2009 | 317 | 0.030 |
Why?
|
| Virulence | 2 | 2007 | 262 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 471 | 0.030 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 2 | 2009 | 381 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 296 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 29 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 2015 | 18 | 0.030 |
Why?
|
| Louisiana | 1 | 2015 | 135 | 0.030 |
Why?
|
| Enterotoxins | 1 | 2015 | 82 | 0.030 |
Why?
|
| Nanospheres | 1 | 2014 | 7 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 118 | 0.030 |
Why?
|
| Enterococcus | 1 | 2014 | 31 | 0.030 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 24 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 95 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 105 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2005 | 2825 | 0.030 |
Why?
|
| Metronidazole | 1 | 2014 | 155 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 93 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 150 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 46 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 342 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2013 | 106 | 0.030 |
Why?
|
| United States | 3 | 2018 | 10885 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 193 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 230 | 0.030 |
Why?
|
| Phospholipids | 1 | 2013 | 106 | 0.020 |
Why?
|
| Biofilms | 1 | 2013 | 92 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 222 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 757 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 389 | 0.020 |
Why?
|
| APACHE | 1 | 2011 | 53 | 0.020 |
Why?
|
| Species Specificity | 2 | 2005 | 550 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 217 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 1325 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 8987 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 731 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 356 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 133 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1163 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2009 | 266 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 723 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2903 | 0.020 |
Why?
|
| Tuberculin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2880 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2007 | 18 | 0.020 |
Why?
|
| Aerosols | 1 | 2007 | 65 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 768 | 0.020 |
Why?
|
| Gene Expression | 2 | 2004 | 1570 | 0.020 |
Why?
|
| Ruminants | 1 | 2005 | 2 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1495 | 0.020 |
Why?
|
| Nitrites | 1 | 2006 | 46 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 84 | 0.020 |
Why?
|
| Horses | 1 | 2005 | 89 | 0.020 |
Why?
|
| Fishes | 1 | 2005 | 42 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 54 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1783 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 113 | 0.020 |
Why?
|
| Primates | 1 | 2005 | 80 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 4783 | 0.020 |
Why?
|
| Sheep | 1 | 2005 | 215 | 0.020 |
Why?
|
| Polyproteins | 1 | 2004 | 8 | 0.010 |
Why?
|
| Chickens | 1 | 2005 | 638 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 4607 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 48 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 152 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 2005 | 173 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 133 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2005 | 165 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 566 | 0.010 |
Why?
|
| Pleural Cavity | 1 | 2004 | 6 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 247 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 465 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2004 | 237 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 129 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1291 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 3726 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 6309 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 782 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 867 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1173 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2771 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2006 | 747 | 0.010 |
Why?
|
| Cosmids | 1 | 1998 | 48 | 0.010 |
Why?
|
| Siderophores | 1 | 1998 | 10 | 0.010 |
Why?
|
| Salmonella | 1 | 1998 | 28 | 0.010 |
Why?
|
| Operon | 1 | 1998 | 52 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1998 | 188 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 17746 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 147 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 209 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 19329 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 658 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 892 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 626 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 449 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 4431 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 4357 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 16299 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 986 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 1761 | 0.010 |
Why?
|